• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Tvardi Therapeutics, Inc. - Common Stock (NQ:TVRD)

4.650 -0.010 (-0.21%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 31, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Tvardi Therapeutics, Inc. - Common Stock

TVRD Investors Have Opportunity to Join Tvardi Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
October 31, 2025
From The Schall Law Firm
Via Business Wire
TVRD INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics
October 30, 2025
From Faruqi & Faruqi LLP
Via GlobeNewswire
TVRD INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics
October 26, 2025
From Faruqi & Faruqi LLP
Via GlobeNewswire
Rosen Law Firm Encourages Tvardi Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation – TVRD
October 24, 2025
From The Rosen Law Firm, P.A.
Via Business Wire
TVRD INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics
October 13, 2025
From Faruqi & Faruqi, LLP
Via Business Wire
Tvardi Therapeutics Provides Update on Preliminary Data from Phase 2 REVERT Trial in Idiopathic Pulmonary Fibrosis
October 13, 2025
From Tvardi Therapeutics, Inc.
Via Business Wire
Tvardi Therapeutics to Participate in the Cantor Global Healthcare Conference
August 21, 2025
From Tvardi Therapeutics, Inc.
Via Business Wire
Tvardi Therapeutics Announces Second Quarter 2025 Results and Provides Business Update
August 14, 2025
From Tvardi Therapeutics, Inc.
Via Business Wire
Tvardi Therapeutics to Participate in the BTIG Virtual Biotechnology Conference
July 15, 2025
From Tvardi Therapeutics, Inc.
Via Business Wire
Tvardi Therapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial of TTI-101 in Idiopathic Pulmonary Fibrosis
May 27, 2025
From Tvardi Therapeutics, Inc.
Via Business Wire
Tvardi Therapeutics to Participate in Upcoming Investor Conferences
May 20, 2025
From Tvardi Therapeutics, Inc.
Via Business Wire
Tvardi Therapeutics Announces First Quarter 2025 Results and Provides Business Update
May 13, 2025
From Tvardi Therapeutics, Inc.
Via Business Wire
Tvardi Therapeutics Announces Presentation at the American Thoracic Society 2025 Annual Conference
May 06, 2025
From Tvardi Therapeutics, Inc.
Via Business Wire
FinancialContent
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap